This paper reviews the aetiology, prevalence and treatment of gynaecomastia. Gynaecomastia is a proliferation of male breast tissue apparently caused by alterations in the ratio of oestrogen : androgen levels. It is common in the general population, resulting from normal physiological changes and various pathological causes. Gynaecomastia is also induced by many drug treatments, including hormonal therapies for prostate cancer. Prophylactic radiotherapy appears to be effective against gynaecomastia in this population. Surgery is an option for intractable cases, and some medical treatments have been reported, although there is a paucity of data evaluating such therapies.
Introduction
Gynaecomastia is a benign proliferation of the male breast tissue, often accompanied by breast pain. In its early stages the condition is characterised by proliferation of both the ®broblastic stroma and ductal tissue. Physical examination reveals a dense mass of subareolar tissue, which feels like coiled rope. 1 With time progressive ®brosis and hyalinisation can occur, which can be irreversible. 2 Gynaecomastia is a common condition resulting from an excess of oestrogen relative to androgen at the site of the breast. It occurs naturally in newborns, boys at puberty and in older men. 3 Although there is often no established aetiology, many pathological causes of gynaecomastia have been determined including congenital defects, endocrinopathies, tumours, chronic disease and drugs, including hormonal therapies for prostate cancer. 4 Hormonal therapies have been used for many years to reduce endogenous androgen production in patients with prostate cancer. Surgical castration is perhaps the oldest treatment, while castration can also be achieved medically using luteinising hormone-releasing hormone (LHRH) analogues. Oestrogens, such as diethylstilboestrol (DES), were the ®rst widely used drug therapy. Both steroidal (cyproterone acetate) and nonsteroidal (¯uta-mide, bicalutamide, nilutamide) antiandrogens have been developed which block the effects of testosterone at the cellular level, and have been used most often in combination with medical or surgical castration (combined androgen blockage [CAB] ). More recently, preliminary results of monotherapy with nonsteroidal antiandrogens suggest equivalent ef®cacy to standard treatments and potential quality-of-life bene®ts. 5 There is no evidence that the addition of antiandrogens to castrated patients is associated with an increase in the incidence of gynaecomastia. However, gynaecomastia is particularly common following oestrogen treatment, and the incidence is also raised in investigational studies of nonsteroidal antiandrogen monotherapy, as predicted by the pharmacological effects of these agents.
The incidence of gynaecomastia among prostate cancer patients receiving hormonal therapy has prompted this review of the aetiology, prevalence and treatment of this condition.
Aetiology
The underlying aetiology of gynaecomastia is thought to be an alteration in the ratio of oestrogen to androgen activity at the site of the breast. 2 In men, the testes produce only a small percentage of circulating oestrogens (maximum 15%); the remainder is formed by peripheral aromatisation of testosterone and androstenedione (from the adrenal glands) in extragonadal tissues. Circulating oestrogens and androgens are bound by sex hormone binding globulin (SHBG). 6 Therefore, there are a number of mechanisms whereby the oestrogen : androgen ratio can be affected, potentially leading to gynaecomastia. These include altered production of hormones, alterations in peripheral aromatisation or interactions with SHBG. Such causes can be further divided into those that are physiological and those that are pathological.
Physiological gynaecomastia occurs in three peaks. There is a transient occurrence associated with high levels of maternal hormones in newborns of both sexes. Gynaecomastia also occurs during puberty, and generally regresses spontaneously within 6 months to 3 years. Pubertal gynaecomastia is thought to be caused by the 24-h activity of oestrogen at the breast, which is unopposed during the daytime when circulating levels of androgens fall to a nadir. 1 Another peak is commonly seen in older men, aged 50 ± 70 y, thought to be associated with decreased levels of testosterone. 3 Many pathologies leading to an increase in circulating oestrogen or a decrease in testosterone have been associated with gynaecomastia. They include endocrinopathies, primary or secondary hypogonadism, hyperthyroidism, adrenal disorders, tumours of the testes, breast, lung, liver, kidney, adrenal and pituitary glands, malnutrition and chronic diseases such as hepatic failure due to cirrhosis, renal failure, human immunode®ciency virus (HIV) infection and pulmonary and nervous system disorders. Additional causes include enhanced breast tissue sensitivity to oestrogens, ingestion of exogenous oestrogens and drug-induced gynaeco-mastia. 6, 7 Approximately 10 ± 20% of presentations with gynaecomastia are drug induced. A wide variety of drugs have been implicated, including hormonal therapies, antibiotics, antiulcer medications, cancer chemotherapeutic agents, cardiovascular drugs, psychotropic drugs, anabolic steroids, drugs of abuse and other miscellaneous compounds (Table 1) . 6, 8 However, the pathophysiology underlying drug-induced gynaecomastia, with the exception of hormonal therapies, is not always well understood.
Exogenous oestrogens, such as DES, directly stimulate breast growth, and hence their administration in men with prostate cancer leads to gynaecomastia. Antiandrogens, which act by blocking the action of androgens at the cellular receptor, may increase the probability of gynaecomastia development in two ways. First, by blocking androgen receptors in the hypothalamic pituitary axis they can inhibit the negative feedback of testosterone on the secretion of luteinising hormone, leading to higher levels of testosterone and, following peripheral aromatisation, higher oestrogen levels. 9 Second, they block the inhibitory effects of circulating androgens at the breast, reinforcing the stimulatory effect of the increased oestrogen activity. A simpli®ed demonstration of the main mechanisms by which gynaecomastia may be induced by oestrogen or antiandrogen therapy for prostate cancer is presented in Figure 1 .
Prevalenceaincidence
Physiological gynaecomastia affects around 60 ± 90% of newborns, 7 and pubertal gynaecomastia has been reported in almost 40% of 10 to 16-year-old boys. 10 Gynaecomastia is also common among adults, with prevalences of between 36 and 72% reported. 3, 11 Druginduced gynaecomastia is the next most common reason for presentation to a physician. 4 In one study, cimetidine, spironolactone and verapamil were associated with a signi®cant increase in the risk of gynaecomastia compared with nonusers (relative risk 7.2, 9.3 and 9.7, respectively, P`0.05). 12 Hormonal therapies for prostate cancer are an obvious cause of gynaecomastia. In controlled studies, gynaecomastia developed in 77 ± 90% of patients treated with oestrogens. 13 ± 15 A lower incidence has been reported following treatment with the LHRH analogue goserelin (5 ± 13%), 16, 17 with a similar incidence reported for the combination of LHRH analogues and nonsteroidal antiandrogens (5 ± 6%). 18 The cancer chemotherapeutic compound estramustine phosphate, which contains oestradiol phosphate, was also associated with gynaecomastia in 37 ± 38% of 88 patients, despite prophylactic irradiation of the breast prior to the initiation of therapy. 19 In a smaller study, gynaecomastia was reported in all patients treated with estramustine phosphate who had not previously received oestrogens. 20 The steroidal antiandrogen cyproterone acetate was associated with gynaecomastia in 6% of subjects with advanced prostate cancer, compared with 40% receiving DES. 21 Gynaecomastia and breast pain have also been observed among a similar proportion of patients receiving nonsteroidal antiandrogens as monotherapy in clinical trials. In a large study,¯utamide monotherapy was associated with breast tenderness in 49% of patients, compared with 14% ± 19% of patients receiving combination therapy with¯utamide and either surgical or medical castration. 22 Gynaecomastia and breast pain developed in 47.1% and 38.8%, respectively, of 314 patients receiving bicalutamide monotherapy, compared with 3.8% and 1.9% among 160 patients treated by castration, in a recent randomised study. 23 In a smaller study 50% of 26 patients receiving nilutamide monotherapy reported gynaecomastia. 24 Although there were relatively few withdrawals from these trials because of gynaecomastia, the patients involved did have advanced prostate cancer. The similarity of the mechanisms of action of the nonsteroidal antiandrogens discussed would lead one to expect a similar incidence of gynaecomastia associated with each of these agents when used as monotherapy.
Treatment
In many cases gynaecomastia may not require active treatment, depending on the etiology. Physiological gynaecomastia in adolescents can be expected to resolve spontaneously, and counselling may be suf®cient. 1 Where the gynaecomastia is caused by underlying conditions, treatment of those conditions may lead to improvement. In drug-related cases, discontinuation of the agent involved may cause regression. 7 However, withdrawal of treatment is usually not an option for patients with prostate cancer as the underlying disease may then progress. Therefore, the breast growth must be suppressed, or a change in treatment considered, such as castration.
The duration of gynaecomastia is important in evaluating possible treatment; gynaecomastia if less than 1 year may respond well to therapy, whereas in cases of longer duration the gynaecomastia may become irreversible. 25 Prophylactic radiotherapy is known to be effective against gynaecomastia among patients receiving hormonal therapy for prostate cancer, while surgery and medical treatment may be options for the treatment of gynaecomastia.
Radiotherapy
The ®rst study to demonstrate prevention of gynaecomastia in prostate cancer patients receiving oestrogens was published in 1962, when Larsson and Sundbom successfully treated six patients with 1000 to 1500 cGy in a single dose. 26 The prophylactic use of radiotherapy since that time is well documented, and a list of English language studies is presented in Table 2 .
Two controlled trials have investigated the ef®cacy of prophylactic radiotherapy in the prevention of gynaecomastia. In a randomised study of 47 patients, Waterfall and Glaser 15 found an incidence of gynaecomastia of 85% following DES therapy, compared with just 11% in those who received prophylactic radiation of 900 cGy in three fractions. Alfthan and Holsti 13 found that gynaecomastia developed in the untreated breast of 90% of 78 patients receiving polyoestradiol phosphate. This was totally or partially inhibited in 83% of breasts treated with either one (800 ± 1250 cGy) or two (800 cGy) doses of radiation. 13 Similarly, among 87 patients treated with DES in conjunction with prophylactic radiotherapy (1200 ± 1500 cGy in three fractions) only 13% developed moderate or severe gynaecomastia, and 17% mammalgia. 29 Although irradiation following the development of gynaecomastia is generally ineffective in reducing breast size, it may be effective in alleviating pain. Alfthan and Kettunen 35 reported relief of soreness and pain among 17 patients with gynaecomastia of 1 to 72 months' duration treated with a single dose of 1425 or 2375 cGy, but gynaecomastia persisted in 9 of 17 cases. Eleven patients with painful gynaecomastia following |DES therapy reported satisfactory pain relief with radiotherapy doses from 2000 cGy in 5 fractions up to 4000 cGy in 20 fractions, persisting in all seven patients for whom 6-month follow-up data were available. 36 However, only 3 of the 11 patients had a decrease in breast size. 
Surgery
In gynaecomastia of long duration, or cases of macrogynaecomastia where extensive ®brosis has taken place, surgery my be the only option. 37 Periareolar subcutaneous mammoplasty is recommended, and should be undertaken by surgeons trained in cosmetic surgery. 38 Adjunctive liposuction has been widely adopted to improve cosmetic results, 39 but in cases of glandular hypertrophy surgical excision is still required. 37 A number of innovations in recent years have been proposed to further improve cosmetic results. These include surgical excision and removal of tissue via the small incisions made for liposuction, 40 and endoscopic techniques which facilitate accurate dissection and haemostasis by enabling visualisation of the procedure. 41 
Medical
There is very little published literature evaluating medical treatment of gynaecomastia. The administration of androgens (particularly dihydrotestosterone, which is not converted to oestradiol in the body) may be effective in cases of idiopathic gynaecomastia, 42 but is obviously contraindicated in the treatment of patients with prostate cancer. The synthetic steroid danazol, a derivative of 17 a-ethinyltestosterone that inhibits the release of pituitary gonadotrophic hormones, has been used to treat idiopathic gynaecomastia. 43, 44 However, its usefulness may be limited by undesirable side effects including nausea, dizziness, skin reactions, mood changes, acne and weight gain. Treatment of gynaecomastia may also be possible by (a) blocking the effects of circulating oestrogens using anti-oestrogens, and (b) blocking the peripheral conversion of androgens to oestrogens with aromatase inhibitors, thereby decreasing levels of circulating oestrogens.
There are several reports of the use of anti-oestrogens (particularly tamoxifen) for the treatment of gynaecomastia. However, the number of controlled studies is few, and it must be remembered that anti-oestrogens such as tamoxifen are not licensed for this indication. In the largest investigational study of tamoxifen treatment, 80% of 61 men had complete regression of idiopathic gynaecomastia. 45 In smaller controlled studies, tamoxifen decreased breast size andaor pain in seven of ten and ®ve of six patients, respectively. 46, 47 More recently, tamoxifen alleviated pain in ®ve of six patient with¯utami-dea®nasteride-induced gynaecomastia, 48 and improved symptoms in three patients with gynaecomastia due to medical or surgical castration. 49 Limited success has been obtained with the antioestrogen clomiphene in 3 small studies. Responses were variable, but in the largest, a good response was seen in 14a22 boys with pubertal gynaecomastia. 50 ± 52 
Conclusions
Gynaecomastia is a common physiological condition, 3 and is also caused by a wide variety of drugs. 8 As one might expect, hormone therapies for prostate cancer, such as oestrogens and the investigational use of nonsteroidal antiandrogen monotherapy, are associated with gynaecomastia. Recent studies have suggested that monotherapy with nonsteroidal antiandrogens may offer similar ef®-cacy to standard treatments, such as castration, but with potential quality-of-life bene®ts. If increasing numbers of patients are to be offered this treatment, effective prevention or relief of gynaecomastia may be necessary.
Although there is a paucity of published literature evaluating medical treatment of gynaecomastia, a number of options have been investigated. Prophylactic radiotherapy appears to be effective in the prevention of gynaecomastia induced by hormonal therapy in patients with prostate cancer; however, it is not as effective when used as a treatment for established gynaecomastia. Surgery is an option for severe or prolonged gynaecomastia, and the adoption of liposuction and other techniques may confer improved cosmetic results. Anti-oestrogens and aromatase inhibitors, which should theoretically be effective in treating gynaecomastia, are not registered for such use, and their role needs to be de®ned further.
